BioPlus Co Ltd
KOSDAQ:099430
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 330
7 700
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
BioPlus Co Ltd
Cash Equivalents
BioPlus Co Ltd
Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
BioPlus Co Ltd
KOSDAQ:099430
|
Cash Equivalents
₩46B
|
CAGR 3-Years
42%
|
CAGR 5-Years
68%
|
CAGR 10-Years
N/A
|
|
|
SD Biosensor Inc
KRX:137310
|
Cash Equivalents
₩482.4B
|
CAGR 3-Years
26%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
H
|
HLB Inc
KOSDAQ:028300
|
Cash Equivalents
₩89.7B
|
CAGR 3-Years
-20%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
T
|
T&L Co Ltd
KOSDAQ:340570
|
Cash Equivalents
₩19.3B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
47%
|
CAGR 10-Years
N/A
|
|
|
H
|
Humasis Co Ltd
KOSDAQ:205470
|
Cash Equivalents
₩9.7B
|
CAGR 3-Years
-49%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
I
|
Interojo Co Ltd
KOSDAQ:119610
|
Cash Equivalents
₩10.4B
|
CAGR 3-Years
12%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
BioPlus Co Ltd
Glance View
BioPlus Co., Ltd. is engaged in the manufacturing and supplying of diverse dermal fillers. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2021-09-27. The firm is engaged in the production and sale of biomaterials for tissue restoration used for temporary improvement of facial wrinkles, namely hyaluronic acid fillers. In addition, the Company is engaged in the production and sale of anti-adhesion agents that reduce the formation of adhesions in surgical areas, biomaterials for joint tissue repair, and other products.
See Also
What is BioPlus Co Ltd's Cash Equivalents?
Cash Equivalents
46B
KRW
Based on the financial report for Dec 31, 2023, BioPlus Co Ltd's Cash Equivalents amounts to 46B KRW.
What is BioPlus Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 5Y
68%
Over the last year, the Cash Equivalents growth was 151%. The average annual Cash Equivalents growth rates for BioPlus Co Ltd have been 42% over the past three years , 68% over the past five years .
You don't have any saved screeners yet
